Citation: | Zhao Xue, Yu Che, Wang Rong. Clinicopathological features of 71 patients with amyloidosis nephropathy[J]. Journal of Clinical Nephrology, 2021, 21(6): 455-462. DOI: 10.3969/j.issn.1671-2390.y20-232 |
[1] |
Jazbeh S,Said A,Haddad RY,et al.Renal amyloidosis[J].Disease-a-month,2014,60(10):489-493.DOI: 10.1016/j.disamonth.2014.08.003.
|
[2] |
Ryšavá R.AL amyloidosis:advances in diagnostics and treatment[J].Nephrol Dial Trans,2019,34(9):1460-1466.DOI: 10.1093/ndt/gfy291.
|
[3] |
Nienhuis HL,Bijzet J,Hazenberg BP.The prevalence and management of systemic amyloidosis in western countries[J].Kidney Dis(Basel),2016,2(1):10-19.DOI: 10.1159/000444206.
|
[4] |
Benson MD,Buxbaum JN,Eisenberg DS,et al.Amyloid nomenclature 2018:recommendations by the International Society of Amyloidosis(ISA)nomenclature committee[J].Amyloid,2018,25(4):215-219.DOI: 10.1080/13506129.2018.1549825.
|
[5] |
Kastritis E,Gavriatopoulou M,Roussou M,et al.Renal outcomes in patients with AL amyloidosis:Prognostic factors,renal response and the impact of therapy[J].Am J Hematol,2017,92(7):632-639.DOI: 10.1002/ajh.24738.
|
[6] |
Kellum JA,Lameire N,KDIGO AKI Guideline Work Group.Diagnosis,evaluation,and management of acute kidney injury:a KDIGO summary(Part 1)[J].Crit Care,2013,17(1):204.DOI: 10.1186/cc11454.
|
[7] |
Levey AS,Eckardt KU,Tsukamoto Y,et al.Definition and classification of chronic kidney disease:a position statement from Kidney Disease:Improving Global Outcomes(KDIGO)[J].Kidney Int,2005,67(6):2089-2100.DOI: 10.1111/j.1523-1755.2005.00365.x.
|
[8] |
Atkin C,Richter A,Sapey E.What is the significance of monoclonal gammopathy of undetermined significance?[J].Clin Med(Lond),2018,18(5):391-396.DOI: 10.7861/clinmedicine.18-5-391.
|
[9] |
Leung N,Bridoux F,Hutchison CA,et al.Monoclonal gammopathy of renal significance:when MGUS is no longer undetermined or insignificant[J].Blood,2012,120(22):4292-4295.DOI: 10.1182/blood-2012-07-445304.
|
[10] |
Said SM,Sethi S,Valeri AM,et al.Renal amyloidosis:origin and clinicopathologic correlations of 474 recent cases[J].Clin J Am Soc Nephrol,2013,8(9):1515-1523.DOI: 10.2215/CJN.10491012.
|
[11] |
Panizo N,Rivera F,López-Gómez JM,et al.Decreasing incidence of AA amyloidosis in Spain[J].Eur J Clin Invest,2013,43(12):1371.DOI: 10.1111/eci.12156.
|
[12] |
Kyle RA,Gertz MA.Primary systemic amyloidosis:clinical and laboratory features in 474 cases[J].Semin Hematol,1995,32(1):45-59.
|
[13] |
Yao Y,Wang SX,Zhang YK,et al.A clinicopathological analysis in a large cohort of Chinese patients with renal amyloid light-chain amyloidosis[J].Nephrol Dial Trans,2013,28(3):689-697.DOI: 10.1093/ndt/gfs501.
|
[14] |
向流霞,袁曙光,张新民,等.76例淀粉样变性肾损害的临床病理特点[J].临床与病理杂志,2018,38(8):1675-1681.DOI: 10.3978/j.issn.2095-6959.2018.08.013.
Xiang LX,Yuan SG,Zhang XM,et al.Clinicopathological features of renal impairment in 76 cases with amyloidosis[J].Int J Pathol Clin Med,2018,38(8):1675-1681.DOI: 10.3978/j.issn.2095-6959.2018.08.013.
|
[15] |
姚英,章友康,王素霞.AL型肾淀粉样变的临床病理特点和治疗进展[J].中华临床医师杂志(电子版),2012,6(15):4180-4181.DOI: 10.3877/cma.j.issn.1674-0785.2012.15.005.
Yao Y,Zhang YK,Wang SX.Clinicopathological characteristics and treatment progress of AL renal amyloidosis[J].Chin J Clin Electron Ed,2012,6(15):4180-4181.DOI: 10.3877/cma.j.issn.1674-0785.2012.15.005.
|
[16] |
Ji C,Su Y,Zhang C,et al.Reference intervals for hemoglobin and age-and gender-related trends in the population of southwest China[J].Clin Lab,2015,61(12):1831-1836.DOI: 10.7754/clin.lab.2015.150423.
|
[17] |
Gertz MA,Comenzo R,Falk RH,et al.Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis(AL):a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis,Tours,France,18-22 April 2004[J].Am J Hematol,2005,79(4):319-328.DOI: 10.1002/ajh.20381.
|
[18] |
姚英,王素霞,章友康,等.国人190例免疫球蛋白轻链型淀粉样变性病临床与病理的相关性分析[J].中华临床医师杂志(电子版),2013,7(14):6344-6348.DOI: 10.3969/cma.j.issn.1674-0785.2013.14.031.
Yao Y,Wang SX,Zhang YK,et al.Associations between pathological features and clinical manifestations of immunoglobulin light-chain renal amyloidosis[J].Chin J Clin Electron Ed,2013,7(14):6344-6348.DOI: 10.3969/cma.j.issn.1674-0785.2013.14.031.
|
[19] |
Itabashi M,Takei T,Tsukada M,et al.Association between clinical characteristics and AL amyloid deposition in the kidney[J].Heart Vessels,2010,25(6):543-548.DOI: 10.1007/s00380-010-0019-y.
|
[20] |
陆怡敏.87例肾淀粉样变的临床病理研究[D].上海:上海交通大学,2008:1-55.
Lu YM.Clinico-pathological Study of 87 patients of renal amyloidosis[D].Shanghai:Shanghai Jiaotong University,2008:1-55.
|
[21] |
Klomjit N,Leung N,Fervenza F,et al.Rate and predictors of finding monoclonal gammopathy of renal significance(MGRS)lesions on kidney biopsy in patients with monoclonal gammopathy[J].J Am Soc Nephrol,2020,31(10):2400-2411.DOI: 10.1681/ASN.2020010054.
|
[22] |
Kyle RA,Therneau TM,Rajkumar SV,et al.A long-term study of prognosis in monoclonal gammopathy of undetermined significance[J].N Engl J Med,2002,346(8):564-569.DOI: 10.1056/NEJMoa01133202.
|
[23] |
Nasr SH,Satoskar A,Markowitz GS,et al.Proliferative glomerulonephritis with monoclonal IgG deposits[J].J Am Soc Nephrol,2009,20(9):2055-2064.DOI: 10.1681/ASN.2009010110.
|
[24] |
Andeen NK,Troxell ML,Riazy M,et al.Fibrillary glomerulonephritis:clinicopathologic features and atypical cases from a multi-institutional cohort[J].Clin J Am Soc Nephrol,2019,14(12):1741-1750.DOI: 10.2215/cjn.03870319.
|
[25] |
Hetzel GR,Uhlig K,Mondry A,et al.AL-amyloidosis of the kidney initially presenting as minimal change glomerulonephritis[J].Am J Kid Dis,2000,36(3):630-635.DOI: 10.1053/ajkd.2000.16205.
|
[26] |
Sayed RH,Gilbertson JA,Hutt DF,et al.Misdiagnosing renal amyloidosis as minimal change disease[J].Nephrol Dial Trans,2014,29(11):2120-2126.DOI: 10.1093/ndt/gfu242.
|
[27] |
Tsuji K,Arai H,Furusu A,et al.A case of membranoproliferative glomerulonephritis and AA amyloidosis complicated with pulmonary nontuberculous mycobacterial infection[J].CEN Case Rep,2015,4(1):24-30.DOI: 10.1007/s13730-014-0134-1.
|
[28] |
Rosenstock JL,Markowitz GS.Fibrillary glomerulonephritis:an update[J].Kidney Int Rep,2019,4(7):917-922.DOI: 10.1016/j.ekir.2019.04.013.
|
[29] |
Schwartz MM,Korbet SM,Lewis EJ.Immunotactoid glomerulopathy[J].J Am Soc Nephrol,2002,13(5):1390-1397.DOI: 10.1097/01.asn.0000013397.06964.19.
|
[30] |
Chen TT,Achan A,Li K,et al.Collagenofibrotic glomerulopathy[J].Nephrology(Carlton),2018,23(6):601-602.DOI: 10.1111/nep.13107.
|
[31] |
Wang Q,Jiang F,Xu GS.The pathogenesis of renal injury and treatment in light chain deposition disease[J].J Transl Med,2019,17(1):387.DOI: 10.1186/s12967-019-02147-4.
|
[32] |
Nasr SH,Fogo AB.New developments in the diagnosis of fibrillary glomerulonephritis[J].Kidney Int,2019,96(3):581-592.DOI: 10.1016/j.kint.2019.03.021.
|
[33] |
Nasr SH,Vrana JA,Dasari S,et al.DNAJB9 is a specific immunohistochemical marker for fibrillary glomerulonephritis[J].Kid Int Rep,2018,3(1):56-64.DOI: 10.1016/j.ekir.2017.07.017.
|
1. |
耿倩,蔡艳,周竹,范志立. AL型肾淀粉样变一例报道. 云南医药. 2023(02): 116-118 .
![]() | |
2. |
陈巧玲,林婉君,廖永根,叶秋萍,刘丽芳,魏立新. 单中心成人特发性膜性肾病的临床病理特点和预后分析. 中国医学创新. 2022(24): 59-65 .
![]() |